新型雄激素受体降解剂的设计,合成和生物活性评估,基于疏水性标记
Ying Sun1, Huating Wang2, Yaru Li1
1School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
Bioorganic chemistry
|March 27, 2024
概括
研究人员开发了针对雄激素受体 (AR) 的新型PROTAC-HyT降解剂,用于治疗转移性割抵抗性前列腺癌 (mCRPC). 化合物D-4-6显示显著的AR降解和抑制前列腺癌细胞增殖,提供了一个新的治疗途径.
科学领域:
- 药用化学 医学化学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 前列腺癌 (PCa) 往往会发展为致命的转移性割抵抗性前列腺癌 (mCRPC).
- 与雄激素受体 (AR) 相关的转录驱动前列腺瘤细胞的生长.
- 针对AR对于mCRPC治疗至关重要.
研究的目的:
- 设计,合成和评估基于AR降解的疏水标记 (HyT) 的新型蛋白质分解向奇梅拉 (PROTAC).
- 研究这些PROTAC-HyT AR降解剂在抑制前列腺癌细胞增殖中的有效性.
主要方法:
- 合成PROTAC-HyT化合物,通过基链将AR抗剂 (RU59063) 与基于阿达曼坦的疏水分子连接起来.
- 在前列腺癌细胞中评估AR蛋白降解活性.
- 使用IC50值对细胞增殖抑制的评估.
主要成果:
- 化合物D-4-6显示显著的AR蛋白降解 (57%在5μM,~90%在20μM在24小时).
- D-4-6以时间和度依赖的方式抑制LNCaP细胞增殖,IC50为4.77 ± 0.26μM.
- 这项研究为开发新的mCRPC疗法奠定了基础.
结论:
- 在mCRPC中,PROTAC-HyT技术为AR提供了一个有前途的策略.
- 化合物D-4-6显示出强大的AR降解和抗增殖作用.
- 针对AR的降解剂的进一步优化正在进行中,以提高治疗潜力.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.3K
16:16Genetically-encoded Molecular Probes to Study G Protein-coupled Receptors
Published on: September 13, 2013
15.2K
相关概念视频
01:28Structure-Activity Relationships and Drug Design
716
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
716
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.0K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.0K